News Sentiment

NTRP sentiment intelligence

NextTrip Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 29 relevant articles
Exchange NASDAQ United States
Sector Consumer Cyclical Market context
Industry Travel Services Read-through group
Latest close 2.11 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 29

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.7% over one week, -2.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

NextTrip, Inc. (NTRP) Reports Q1 Loss, Tops Revenue Estimates

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive -2.5% over four weeks
Fair value -27.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 20
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 29
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 7
ACCESS Newswire 6
dars.gov.et 3
Market source 2
simplywall.st 2
marketscreener.com 1
TradingKey 1
MT Newswires 1

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 4
Balance sheet 3
Deals and strategy 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-29 of 29
Market source Direct company coverage

Investors Who Bought Neurotrope (NASDAQ:NTRP) Shares Five Years Ago Are Now Down 87%

Neurotrope (NASDAQ:NTRP) shareholders who bought shares five years ago have experienced an 87% loss, despite a recent 38% gain in the last three months. The company, which currently has no revenue, is considered a high-risk investment prone to needing more capital and potential d

Tone
Negative 14/100
Event
Earnings
Published
27 May 2019 12:11
Source
Market source
24/7 Wall St. Direct company coverage

Is Neurotrope the Default Alzheimer’s Winner After Biogen’s Implosion?

Following Biogen and Eisai's decision to halt late-stage studies for their Alzheimer's drug aducanumab, Neurotrope (NASDAQ: NTRP) is being eyed as a potential contender in the Alzheimer's market. Neurotrope's Bryostatin AD therapy, which targets brain synapse loss and moderately

Tone
Positive 65/100
Event
Market update
Published
21 Mar 2019 16:24
Source
24/7 Wall St.
GlobeNewswire Direct company coverage

Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against Neurotrope, Inc. - NTRP

Safirstein Metcalf LLP has announced a class action lawsuit filed against Neurotrope, Inc. (NASDAQ:NTRP) for allegedly issuing materially false and misleading statements regarding the efficacy of its lead product candidate, Bryostatin-1. The lawsuit covers the period between Janu

Tone
Negative 15/100
Event
Regulatory and legal
Published
19 May 2017 17:30
Source
GlobeNewswire